Literature DB >> 8355252

Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.

F Suzuki1, J Shimada, S Shiozaki, S Ichikawa, A Ishii, J Nakamura, H Nonaka, H Kobayashi, E Fuse.   

Abstract

The effects of a variety of adenosine A1 and A2 antagonists on N6-((R)-phenylisopropyl)adenosine (R-PIA)- and scopolamine-induced amnesias were investigated in rodents in order to clarify the role of adenosine receptors in learning and memory. Some of the selective adenosine A1 antagonists exhibited antiamnesic activities at several doses where they did not induce an increase of spontaneous locomotion. These results suggest that the blockade of A1 receptors is more important than that of A2 receptors in learning and memory. Detailed studies of structure-activity relationships of adenosine A1 antagonists in two amnesia models demonstrated that there were three types of adenosine A1 antagonists: (A) Compounds 3-5 (8-substituted 1,3-dipropylxanthines) ameliorated the shortened latency in both models. (B) Compounds 7-11 (8-substituted 1,3-dialkylxanthines) and 19-21 (imidazo[2,1-i]purin-5(4H)-one derivatives) ameliorated the shortened latency in the (R)-PIA-induced amnesia model but not in the scopolamine-induced amnesia model. (C) Compounds 14-16 ameliorated the shortened latency in the scopolamine model but not in the (R)-PIA model. Aminophenethyl-substituted compounds C did not exhibit adenosine A1 antagonism in vivo presumably due to rapid metabolism. The dramatic change in the activities of A and B could not be explained by their simple pharmacokinetic differences because both types of compounds showed clear blockade of central adenosine A1 receptors in the (R)-PIA model. 8-(3-Dicyclopropylmethyl)-1,3-dipropylxanthine (5) (KF15372) was chosen for further studies and is currently under preclinical development as a cognition enhancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8355252     DOI: 10.1021/jm00069a009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Adenosine A(2A) receptors are necessary and sufficient to trigger memory impairment in adult mice.

Authors:  N Pagnussat; A S Almeida; D M Marques; F Nunes; G C Chenet; P H S Botton; S Mioranzza; C M Loss; R A Cunha; L O Porciúncula
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

Review 2.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

3.  Superior working memory and behavioural habituation but diminished psychomotor coordination in mice lacking the ecto-5'-nucleotidase (CD73) gene.

Authors:  Armin Zlomuzica; Sandra Burghoff; Jürgen Schrader; Ekrem Dere
Journal:  Purinergic Signal       Date:  2012-12-29       Impact factor: 3.765

4.  Chronic treatment with DCPCX, an adenosine A(1) antagonist, worsens long-term memory.

Authors:  Craig Vollert; Gloria S Forkuo; Richard A Bond; Jason L Eriksen
Journal:  Neurosci Lett       Date:  2013-06-06       Impact factor: 3.046

5.  Mice lacking the adenosine A1 receptor have normal spatial learning and plasticity in the CA1 region of the hippocampus, but they habituate more slowly.

Authors:  Lydia Giménez-Llort; Susan A Masino; Lihong Diao; Alberto Fernández-Teruel; Adolf Tobeña; Linda Halldner; Bertil B Fredholm
Journal:  Synapse       Date:  2005-07       Impact factor: 2.562

6.  Piracetam prevents scopolamine-induced memory impairment and decrease of NTPDase, 5'-nucleotidase and adenosine deaminase activities.

Authors:  Patricia C Marisco; Fabiano B Carvalho; Michelle M Rosa; Bruna A Girardi; Jessié M Gutierres; Jeandre A S Jaques; Ana P S Salla; Víctor C Pimentel; Maria Rosa C Schetinger; Daniela B R Leal; Carlos F Mello; Maribel A Rubin
Journal:  Neurochem Res       Date:  2013-05-16       Impact factor: 3.996

Review 7.  Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.

Authors:  Jacobus P Petzer; Neal Castagnoli; Michael A Schwarzschild; Jiang-Fan Chen; Cornelis J Van der Schyf
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

8.  DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests.

Authors:  Aleksandra Szopa; Ewa Poleszak; Karolina Bogatko; Elżbieta Wyska; Sylwia Wośko; Urszula Doboszewska; Katarzyna Świąder; Aleksandra Wlaź; Jarosław Dudka; Andrzej Wróbel; Piotr Wlaź; Anna Serefko
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-09       Impact factor: 3.000

9.  C3 amino-substituted chalcone derivative with selective adenosine rA1 receptor affinity in the micromolar range.

Authors:  Helena D Janse van Rensburg; Lesetja J Legoabe; Gisella Terre'Blanche
Journal:  Chem Zvesti       Date:  2020-11-17       Impact factor: 2.097

10.  Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.

Authors:  K A Jacobson; S M Siddiqi; M E Olah; X D Ji; N Melman; K Bellamkonda; Y Meshulam; G L Stiles; H O Kim
Journal:  J Med Chem       Date:  1995-05-12       Impact factor: 7.446

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.